Tserpeli, V.; Stergiopoulou, D.; Londra, D.; Giannopoulou, L.; Buderath, P.; Balgkouranidou, I.; Xenidis, N.; Grech, C.; Obermayr, E.; Zeillinger, R.;
et al. Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer. Cancers 2022, 14, 4.
https://doi.org/10.3390/cancers14010004
AMA Style
Tserpeli V, Stergiopoulou D, Londra D, Giannopoulou L, Buderath P, Balgkouranidou I, Xenidis N, Grech C, Obermayr E, Zeillinger R,
et al. Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer. Cancers. 2022; 14(1):4.
https://doi.org/10.3390/cancers14010004
Chicago/Turabian Style
Tserpeli, Victoria, Dimitra Stergiopoulou, Dora Londra, Lydia Giannopoulou, Paul Buderath, Ioanna Balgkouranidou, Nikolaos Xenidis, Christina Grech, Eva Obermayr, Robert Zeillinger,
and et al. 2022. "Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer" Cancers 14, no. 1: 4.
https://doi.org/10.3390/cancers14010004
APA Style
Tserpeli, V., Stergiopoulou, D., Londra, D., Giannopoulou, L., Buderath, P., Balgkouranidou, I., Xenidis, N., Grech, C., Obermayr, E., Zeillinger, R., Pavlakis, K., Rampias, T., Kakolyris, S., Kasimir-Bauer, S., & Lianidou, E. S.
(2022). Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer. Cancers, 14(1), 4.
https://doi.org/10.3390/cancers14010004
